Riad Mishlawi Acquires 736 Shares of Hikma Pharmaceuticals PLC (LON:HIK) Stock

Hikma Pharmaceuticals PLC (LON:HIK) insider Riad Mishlawi bought 736 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were purchased at an average cost of GBX 1,979 ($24.86) per share, for a total transaction of £14,565.44 ($18,298.29).

Hikma Pharmaceuticals Trading Down 0.2 %

Shares of LON HIK opened at GBX 1,970 ($24.75) on Thursday. The company has a current ratio of 1.57, a quick ratio of 1.27 and a debt-to-equity ratio of 53.92. Hikma Pharmaceuticals PLC has a one year low of GBX 1,711 ($21.49) and a one year high of GBX 2,222 ($27.91). The business has a 50-day moving average price of GBX 1,877.74 and a two-hundred day moving average price of GBX 1,863.02. The firm has a market capitalization of £4.37 billion, a PE ratio of 2,900.00, a PEG ratio of 2.38 and a beta of 0.44.

Hikma Pharmaceuticals Increases Dividend

The business also recently disclosed a dividend, which was paid on Friday, May 3rd. Investors of record on Thursday, March 21st were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Thursday, March 21st. This is an increase from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a yield of 1.86%. Hikma Pharmaceuticals’s payout ratio is presently 8,382.35%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Barclays reiterated an “equal weight” rating and issued a GBX 2,000 ($25.13) target price on shares of Hikma Pharmaceuticals in a report on Tuesday. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 2,000 ($25.13) price target on shares of Hikma Pharmaceuticals in a report on Thursday, April 25th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of GBX 2,068.75 ($25.99).

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.